Press Release Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer 9 hours ago
Press Release Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Aug 6